12:00 AM
 | 
Oct 24, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Luminate: Phase IIb data

The double-blind, U.S. Phase IIb DEL MAR trial in 136 DME patients showed that once-monthly 1 mg Luminate met the primary endpoint of non-inferiority to Avastin bevacizumab in the mean improvement from baseline in BCVA at week 20 (5.2 vs. 7 letters). The non-inferiority margin was a <=3-letter difference. The 1 mg dose...

Read the full 247 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >